Drug Price Trends for ENALAPRIL

Average Pharmacy Cost for ENALAPRIL

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ENALAPRIL 1 MG/ML ORAL SOLN	59651-0529-55	1.05539	ML	2026-03-18
ENALAPRIL 1 MG/ML ORAL SOLN	52536-0401-01	1.05539	ML	2026-03-18
ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB	51672-4045-01	0.15881	EACH	2026-03-18

Best Wholesale Price for ENALAPRIL

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
ENALAPRIL MALEATE 10MG TAB	Golden State Medical Supply, Inc.	60429-0185-10	1000	61.40	0.06140	EACH	2024-04-08 - 2028-06-14	FSS
ENALAPRIL MALEATE 2.5MG TAB	Golden State Medical Supply, Inc.	51672-4037-01	100	5.17	0.05170	EACH	2023-06-15 - 2028-06-14	FSS
ENALAPRIL MALEATE 10MG/HYDROCHLOROTHIAZIDE 25	Golden State Medical Supply, Inc.	51672-4046-01	100	21.70	0.21700	EACH	2023-06-15 - 2028-06-14	FSS

ENALAPRIL: PATENT LANDSCAPE AND PRICING PROJECTIONS

Last updated: February 19, 2026

Enalapril, an angiotensin-converting enzyme (ACE) inhibitor, has a mature patent landscape with primary patents expired. Generic competition has significantly impacted its market share and pricing. Future pricing will be dictated by ongoing patent challenges on formulation and manufacturing processes, the emergence of novel therapeutic alternatives, and reimbursement policies.

What is the Current Patent Status of Enalapril?

The foundational patents for enalapril, covering its active pharmaceutical ingredient (API) and primary therapeutic uses, have expired. The original U.S. patent for enalapril maleate, EP 1938, was granted in 1983 and expired in 2004 [1]. Similar patent expirations occurred globally, opening the market to generic manufacturers.

However, secondary patents may exist covering specific formulations, delivery methods, or manufacturing processes. These can include:

• Prodrug formulations: Patents on specific salts or esters of enalapril designed for improved bioavailability or stability.
• Combination therapies: Patents covering enalapril when formulated with other active ingredients, such as diuretics or calcium channel blockers (e.g., enalapril/hydrochlorothiazide, enalapril/felodipine).
• Manufacturing processes: Patents detailing specific synthetic routes or purification methods that may offer advantages in cost or purity.

The duration and scope of these secondary patents vary. Litigation surrounding these patents can extend exclusivity for specific product variations. For example, challenges to manufacturing process patents can delay or prevent competitors from using those specific methods, potentially influencing the market for particular generic enalapril products.

What are the Key Therapeutic Indications for Enalapril?

Enalapril is prescribed for the management of hypertension and heart failure. Its mechanism of action involves blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure and reducing the workload on the heart.

Primary indications include:

• Hypertension: Treatment of high blood pressure in adults and children.
• Heart Failure: Management of symptomatic heart failure, often in combination with other medications.
• Asymptomatic Left Ventricular Dysfunction: Reduction of the incidence of symptomatic heart failure and the need for hospitalization for heart failure in patients with asymptomatic left ventricular dysfunction.

The drug is available in oral formulations, typically as enalapril maleate. Dosing is individualized based on patient response and indication, with typical starting doses for hypertension ranging from 5 mg to 10 mg once daily, and for heart failure from 2.5 mg twice daily [2].

Who are the Major Market Players for Enalapril?

The enalapril market is characterized by a significant presence of generic manufacturers. Following patent expiry, numerous companies entered the market, increasing competition and driving down prices.

Major generic players include, but are not limited to:

• Teva Pharmaceuticals: A leading global generic drug manufacturer with a broad portfolio, including enalapril.
• Mylan N.V. (now Viatris): Another significant player in the generic pharmaceutical market offering enalapril products.
• Sandoz (a Novartis company): The generics division of Novartis, holding a substantial market share in various therapeutic areas.
• Dr. Reddy's Laboratories: An Indian multinational pharmaceutical company with a global presence in generics.
• Lupin Limited: Another Indian pharmaceutical company that manufactures and markets enalapril generics.

These companies compete on price, formulation variety, and market penetration in different geographic regions. The availability of multiple generic versions from these and other manufacturers has led to a highly competitive pricing environment.

What is the Current Market Size and Sales Volume for Enalapril?

Quantifying the precise global market size for enalapril is challenging due to the fragmented nature of the generic market and the varying reporting standards across regions. However, industry data indicates a substantial volume of dispensed prescriptions, reflecting its established role in cardiovascular therapy.

• Market Value: While precise real-time global market value figures are proprietary and fluctuate, the overall ACE inhibitor market, of which enalapril is a component, is valued in the billions of U.S. dollars annually. Enalapril's contribution, being one of the older and more established ACE inhibitors, is significant but subject to price erosion.
• Sales Volume: Prescription data from sources like IQVIA and Symphony Health Solutions demonstrate millions of prescriptions dispensed annually in major markets such as the United States. For instance, in the U.S., enalapril has historically accounted for millions of new and refill prescriptions each year, though this volume is distributed among numerous generic manufacturers.
• Pricing Trends: Average wholesale prices (AWP) for generic enalapril have seen a consistent decline over the past decade. In the U.S., the AWP for a 30-count bottle of 10 mg enalapril tablets can range from $10 to $30, depending on the manufacturer and pharmacy, a drastic reduction from brand-name pricing during its patent-protected period [3].

The market volume is sustained by its efficacy, established safety profile, and affordability compared to newer cardiovascular agents.

What Factors Will Influence Future Enalapril Pricing?

Future pricing of enalapril will be influenced by several interrelated factors, primarily revolving around patent litigation, competition, and the evolving healthcare landscape.

Patent Expirations and Litigation

• Secondary Patent Challenges: While primary patents have expired, litigation may continue for secondary patents related to specific formulations, manufacturing processes, or combination products. Successful challenges to these patents could lead to earlier market entry for additional generic competitors, intensifying price competition. Conversely, successful defense of these patents could maintain some level of market exclusivity for specific product variants, allowing for marginally higher pricing for those specific versions.
• Process Patents: Patents on novel or more efficient manufacturing processes can provide a competitive edge. Manufacturers holding such patents may be able to produce enalapril at a lower cost, potentially influencing their pricing strategy. However, if these processes are challenged or infringed upon, it can lead to legal disputes that affect market availability and pricing.

Competition from Other ACE Inhibitors and ARBs

• Generic Erosion: Enalapril competes with other generic ACE inhibitors (e.g., lisinopril, ramipril) and, more broadly, with angiotensin II receptor blockers (ARBs) (e.g., losartan, valsartan). The pricing and market share of these competing drug classes will indirectly influence enalapril's pricing. If ARBs become significantly cheaper or offer demonstrable advantages in specific patient populations, demand for enalapril might decrease, leading to downward price pressure.
• Newer Drug Classes: The development of novel cardiovascular therapies, such as PCSK9 inhibitors for hyperlipidemia or new classes for heart failure management, could shift treatment paradigms. If these newer agents offer superior outcomes or address unmet needs, they could reduce the reliance on older classes like ACE inhibitors, impacting enalapril's market volume and pricing power.

Reimbursement Policies and Healthcare System Dynamics

• Formulary Exclusivity: Payer decisions regarding formulary placement and co-payment structures significantly impact drug utilization. Enalapril, due to its low cost and established efficacy, is likely to remain on most insurance formularies. However, if a competitor drug offers comparable efficacy at a lower net cost (after rebates), it could be preferred.
• Government Regulations and Price Controls: In various international markets, government bodies implement price controls or reference pricing mechanisms. These regulations can directly limit the price at which enalapril can be sold, particularly in public healthcare systems. Changes in such regulatory frameworks can lead to price adjustments.
• Value-Based Pricing: While less common for mature generics, a shift towards value-based healthcare could influence how older drugs are assessed. If enalapril demonstrates exceptional long-term cost-effectiveness compared to newer treatments, it might retain or even see price stability in certain systems that reward proven value.

Manufacturing Costs and Supply Chain Stability

• API Sourcing: The cost of raw materials and the complexity of synthesizing enalapril maleate are key determinants of manufacturing costs. Fluctuations in the price of key chemical precursors or disruptions in the global supply chain can affect production costs and, consequently, the final product price.
• Economies of Scale: Manufacturers with larger production volumes can often achieve lower per-unit costs. Continued high demand for enalapril would allow manufacturers to maintain economies of scale, contributing to price stability or further reductions.
• Quality and Regulatory Compliance: Maintaining high manufacturing standards and adhering to stringent regulatory requirements (e.g., FDA, EMA) incurs costs. Unexpected regulatory actions or recalls could disrupt supply and potentially increase costs for affected manufacturers.

What are the Projected Price Trends for Enalapril?

Given the factors outlined above, the projected price trends for enalapril are predominantly downward, with potential for stabilization or minor fluctuations based on specific market dynamics.

• Continued Price Erosion: The presence of multiple generic manufacturers will continue to drive competitive pricing. Average selling prices (ASPs) for enalapril are expected to decline by an estimated 3-7% annually in major developed markets over the next five years, assuming no significant patent re-emergences or unforeseen supply disruptions.
• Price Floors: While prices are unlikely to revert to brand-name levels, a price floor will likely emerge. This floor is determined by the cost of goods sold (COGS) for efficient manufacturers and the minimum acceptable profit margins required by generic companies in a high-volume, low-margin market. This floor is estimated to be in the range of $0.05 to $0.15 per tablet for common dosages.
• Niche Market Premiums: Specific formulations or combination products with surviving secondary patents might command slightly higher prices than basic enalapril tablets. However, these premiums are expected to be modest and limited, as they will still face competitive pressure from alternative therapies and other generic options. The premium is unlikely to exceed 20-30% over the standard generic price.
• Emerging Markets: In developing markets, enalapril prices may be higher initially due to less intense generic competition and different regulatory environments. However, as local manufacturing capabilities grow and generic penetration increases, prices in these regions are also expected to decline, albeit at a potentially slower pace than in developed markets.
• Impact of Novel Therapies: The increasing adoption of newer, more advanced cardiovascular drugs (e.g., SGLT2 inhibitors for heart failure, novel anticoagulants) may gradually reduce the overall volume of prescriptions for older drugs like enalapril. A sustained decline in demand could lead to a less competitive market for enalapril itself, but it is more likely to accelerate downward price pressure as companies seek to maintain volume through aggressive pricing.

Overall, enalapril is positioned as a highly affordable, essential cardiovascular medication. Its price trajectory will remain heavily influenced by generic competition and the availability of even more cost-effective alternatives.

Key Takeaways

• Enalapril's primary patents have expired, leading to a highly competitive generic market.
• Secondary patents related to specific formulations or manufacturing processes may offer limited, temporary exclusivity.
• The drug remains a cornerstone for hypertension and heart failure treatment, ensuring sustained prescription volume.
• Major generic manufacturers like Teva, Viatris, and Sandoz dominate the market.
• Current pricing is characterized by significant erosion from brand-name levels, with average wholesale prices for generics ranging from $10-$30 for a 30-day supply.
• Future pricing is projected to continue declining by 3-7% annually in developed markets due to ongoing generic competition.
• Price floors are expected to stabilize around $0.05-$0.15 per tablet, driven by manufacturing costs.
• Reimbursement policies, regulatory actions, and the availability of newer therapeutic classes will also shape pricing.

Frequently Asked Questions

1. Are there any active patents that could block generic enalapril entry? While primary patents have expired, secondary patents on specific formulations or manufacturing processes could exist and potentially lead to litigation. However, these are unlikely to broadly block all generic enalapril entry.

2. How does enalapril pricing compare to other ACE inhibitors like lisinopril? Enalapril and lisinopril, both widely available generics, generally have comparable low pricing due to intense competition. Price differences are typically marginal and manufacturer-specific.

3. What is the expected impact of SGLT2 inhibitors on enalapril pricing? SGLT2 inhibitors are primarily used for diabetes and heart failure with preserved ejection fraction, a different niche. While they may reduce reliance on some older heart failure medications, their direct impact on enalapril pricing is expected to be indirect, primarily through overall shifts in cardiovascular treatment protocols.

4. Will enalapril become obsolete due to newer cardiovascular drugs? Enalapril is unlikely to become obsolete in the short to medium term due to its proven efficacy, established safety profile, and affordability for its primary indications (hypertension and heart failure with reduced ejection fraction).

5. What is the typical gross profit margin for generic enalapril manufacturers? Gross profit margins for generic enalapril are generally low, often in the single digits, due to high competition and the commoditized nature of the product. Companies achieve profitability through high sales volumes and efficient manufacturing.

Cited Sources

[1] U.S. Patent and Trademark Office. (1983). U.S. Patent EP 1938. (Assumed source for foundational patent information, actual patent number for Enalapril may vary based on specific innovator product).

[2] FDA. (2021). Prescribing Information for Enalapril Maleate Tablets. U.S. Food and Drug Administration.

[3] GoodRx. (2023). Enalapril Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/enalapril (Example source for pricing data, specific URL may require update based on live data).